About Agios
Agios is a company based in Cambridge (United States) founded in 2008. It operates as a HealthTech. Agios has raised $128.65 million across 8 funding rounds from investors including HHS, Flagship Pioneering and Celgene. The company has 488 employees. Agios offers products and services including Therapies for Rare Diseases and Hemolytic Anemia Treatments. Agios operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Annual Revenue$54.03 M (USD)48.03as on Dec 31, 2025
- Net Profit-$412.78 M (USD)-161.27as on Dec 31, 2025
- EBITDA-$466.95 M (USD)-11.16as on Dec 31, 2025
- Total Equity Funding$128.65M (USD)
in 8 rounds
- Latest Funding Round$400.56K (USD), Post-IPO
Oct 2017
- InvestorsHHS
& 4 more
- Employee Count488
Products & Services of Agios
Agios offers a comprehensive portfolio of products and services, including Therapies for Rare Diseases and Hemolytic Anemia Treatments.
Therapies are developed for rare hematologic diseases.
Treatments are focused on hemolytic anemia conditions.
Funding Insights of Agios
Agios has successfully raised a total of $128.65M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $400.56 thousand completed in October 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $128.65M
- Total Rounds 8
- Last Round Post-IPO — $400,560
- First Round $33M
(Jul 2008)
- Investors Count 5
All 8 funding rounds of Agios with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2017 | $400,560 | Post-IPO | – | – | – |
| Sep 2016 | $173M | Post-IPO | – | – | – |
| Nov 2011 | $78M | Series C | – | Celgene, Arch Venture Partners | – |
| Feb 2011 | $67,500 | Grant | – | – | |
| Feb 2011 | $67,500 | Grant | – | – | |
| Apr 2010 | $8.82M | Series A | – | – | – |
| Apr 2010 | $8.82M | Series A | – | – | – |
| Jul 2008 | $33M | Series A | – | Arch Venture Partners, Third Rock Ventures | – |
5 investors in total: 5 institutional.
Investors in Agios
Agios has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Flagship Pioneering and Celgene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Venture capital funding is provided to early-stage life science companies. | – | thirdrockventures.com | Boston, United States | |
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
Therapies for cancer and inflammatory diseases are developed. | 1986 | celgene.com | Summit, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for Agios
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Agios
231 people are tracked at Agios (151 in leadership, 1 in board & advisors, 79 in team); the tracked headcount is 488.
| Name | Role | Group |
|---|---|---|
Tsveta Milanova | Chief Commercial Officer | Leadership |
Jim Burns | Chief Legal Officer | Leadership |
Raymond Burgos | Associate Director Clinical Operations | Leadership |
Kelly Heuer | Associate Director, Global Safety Scientist | Leadership |
Clive Patience | Chief Technical Operations Officer | Leadership |
Kelly Kemp | Associate Director Medical Operations | Leadership |
Maggie Grasso | Senior Director Clinical Operations | Leadership |
Hui Gao | Senior Director, Head Of Discovery & Translational Research | Leadership |
Dan Paquette | Director Site Operations | Leadership |
Mike McNulty | Senior Director Commercial Excellence And Operations | Leadership |
Parija Patel Pharmd, Rph | Senior Medical Director, Global Medical Affairs - Rare Genetic Diseases | Leadership |
Vanessa Beynon | Senior Medical Director, Clinical Development | Leadership |
Karina Fedak | Associate Manager, HR Business Partner | Leadership |
Wendy Martin | Director, Commercial Analytics | Leadership |
Srivathsa Ravikiran | Associate Director, Statistical Programming | Leadership |
Lacey Buckley | Associate Director, Patient Services & Market Access | Leadership |
Krishnan Viswanadhan | Chief Corporate Development And Strategy Officer | Leadership |
Katie Sousa | Director Clinical Data Management | Leadership |
Kim Porter | Director | Leadership |
Deepanshu Arora | Associate Director, Commercial Advanced Analytics | Leadership |
211 more people are available in the full profile.
Complete people profiles for Agios
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Agios
Agios is a publicly listed company on the NASDAQ with ticker symbol AGIO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date09 Aug 2013
- Listed onFRA: 8AP AGIO
- Listed entityAgios Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS00847X1046
- Share price$31.81 (-0.34% on the day) · 2026-10-09
- Market capitalisation$1.90B
- EPS (diluted, trailing year)$-7.01
- Volume (last session)835,681
Financials of Agios
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $54.0M | -$412.8M | -$466.9M |
| 2024 | $36.5M | $673.7M | -$420.1M |
| 2023 | $26.8M | -$352.1M | -$384.9M |
| 2022 | $14.2M | -$231.8M | -$370.5M |
| 2021 | – | -$384.4M | -$359.6M |
Detailed financial statements for Agios
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Agios
4 dated milestones of Agios across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Agios is founded.
- Funding First funding round of $33.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $401K.
Competitors of Agios
Agios operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | |
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| sanofigenzyme.com | 1981 | Cambridge, United States | – | – | Antibody-drug conjugates are developed for treating multiple diseases. | |
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. |
Detailed competitors of Agios
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Agios
The website of Agios (agios.com) receives about 21.8K visits a month and ranks #1,284,134 among all websites worldwide, #1,636 in Biotechnology and Pharmaceuticals.
- Monthly visits21.8K
▲ 1.3% vs previous month
- Unique visitors9K
per month
- Global rank#1,284,134
among all websites
- Category rank#1,636
Health · Biotechnology and Pharmaceuticals
- Bounce rate46%
- Pages per visit1.8
- Average visit47 sec
- DevicesDesktop 44% · Mobile 56%
Websites whose visitors overlap most with Agios. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| bluebirdbio.com | 100% | 9.1K | #3,210,476 | View details | |
| epizyme.com | 99% | – | – | View details | |
| acceleronpharma.com | 91% | – | – | View details | |
| foundationmedicine.com | 83% | 65K | #611,310 | View details | |
| alkermes.com | 79% | 22.7K | #1,117,011 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for Agios
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Agios
Complete news archive for Agios
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Agios
10 companies that operate in the same segment as Agios (Rare Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing. | 2013 | Basel, Basel-stadt, Switzerland | USD 127 M | USD 37.31 M | 393 | |
Gene therapies for rare diseases are developed to treat patients. | 2020 | Columbus, Ohio, United States | USD 250 M | – | – | |
Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | 2015 | Cambridge, Massachusetts, United States | USD 114.67 M | – | 45 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals. | 2019 | Menlo Park, California, United States | USD 90 M | USD 175.11 M | 427 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Agios
Agios was founded in 2008.
Agios is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Agios is a funded company, having raised a total of $128.65M across 8 funding rounds to date. The company's 1st funding round was a Series A of $33M, raised on Jul 2008.
Agios has 488 employees.
Annual revenue of Agios is $54.03M as on Dec 31, 2025.
Agios is engaged in the development of groundbreaking therapies targeting rare diseases, with a primary focus on hemolytic and acquired anemias such as pyruvate kinase deficiency, thalassemia, and sickle cell disease. The company is recognized for its pioneering leadership in cellular metabolism, which forms the foundation of its scientific advancements. Therapies are designed to offer disease-modifying and long-term effects rather than merely palliative care. Collaboration with patient communities, healthcare professionals, and partners is emphasized to ensure that patient needs are addressed effectively. A strong portfolio of therapeutic candidates is being built to meet unmet medical needs in specialized sectors of healthcare.
Agios's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Agios offers Therapies for Rare Diseases and Hemolytic Anemia Treatments.
Yes, Agios is publicly traded on NASDAQ under the ticker symbol AGIO.
Agios has 5 investors. Key investors include HHS, Flagship Pioneering, Celgene, Arch Venture Partners, and Third Rock Ventures.
Agios operates through Agios Pharmaceuticals.